InDex Pharmaceuticals has announced that its CEO Jenny Sundqvist and its CFO & Deputy CEO Johan Giléus will leave the company per September 26, 2024.

Jenny Sundqvist and Johan Giléus will both remain in their positions and at the company’s disposal until their last day of employment.

Read more: InDex Pharmaceuticals discontinues phase III program

“I would like to thank Jenny and Johan for their valuable contributions and for a very good collaboration. Unfortunately, our phase III study did not deliver as we had hoped for, and all current operations are being closed down. I wish both Jenny and Johan the best of luck and am certain that they will be as appreciated in their next endeavors as they have been at InDex,” said Wenche Rolfsen, Chairman of the Board of InDex Pharmaceuticals.

Photo of Johan Giléus and Jenny Sundqvist: InDex Pharmaceuticals